What's Happening?
Bristol Myers Squibb has received approval from the European Commission to expand the use of its CAR T cell therapy, Breyanzi, for treating adult patients with relapsed or refractory mantle cell lymphoma
(MCL) after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase inhibitor. The approval is based on the TRANSCEND MCL trial results, which showed a high overall response rate of 82.7% and a complete response rate of 71.6%. Breyanzi demonstrated sustained clinical benefits, with 50.8% of patients still in response at 24 months.
Why It's Important?
This approval marks a significant advancement in the treatment options available for mantle cell lymphoma, a rare and aggressive form of non-Hodgkin lymphoma. Breyanzi's expanded use could address a critical treatment gap for patients who relapse or become resistant to existing therapies. The approval reinforces Bristol Myers Squibb's leadership in cell therapy and its commitment to delivering innovative treatments for blood cancers, potentially improving survival outcomes for patients across Europe.
